Abiraterone Cougar Biotechnology

IDrugs

Volumn 9, Issue 1, 2006, Pages 49-55

  Madan, Ravi A ^a   Arlen, Philip M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CB 7630; CYTOCHROME P450 17; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; NILUTAMIDE; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL STUDY; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; MALE; MUSCLE ATROPHY; NAUSEA; NONHUMAN; OSTEOPENIA; PATENT; PROSTATE CANCER; SCROTAL PAIN; SEXUAL DYSFUNCTION; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANIMALS; CLINICAL TRIALS, PHASE I; ENZYME INHIBITORS; HUMANS; LICENSURE; MALE; MOLECULAR STRUCTURE; NADPH-FERRIHEMOPROTEIN REDUCTASE; PATENTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 31344470356     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. 178328 B Ingelheim's new prostate cancer drug. SCRIP 1995 2029 23
2. 178401 Pharmacology of novel steroidal inhibitors of cytochrome P450 (17)α (17 α-hydroxylase/C17-20 lyase). Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M J STEROID BIOCHEM MOL BIOL 1994 50 5-6 267-273
3. 179810 BTG licensing opportunities. British Technology Group Ltd COMPANY BROCHURE 1995 March
4. 194852 Esters of 3-pyridylacetic acid that combine potent inhibition of 17α-hydroxylase/c17,20-lyase (cytochrome P45017α) with resistance to esterase hydrolysis. Rowlands MG, Barrie SE, Chan F, Houghton J, Jarman M, McCague R, Potter GA J MED CHEM 1995 38 21 4191-4197
5. 222422 Annual Report - Institute of Cancer Research - 1994. Institute of Cancer Research, UK ANNUAL REPORT 1994 December
6. 17α-hydroxylase/C17,20 lyase). Barrie SE, Jarman M ENDOCR-RELAT CANCER 1996 3 25-39
7. 256287 Drug development pipeline: BILD-1263, BILD-1351, BIBR-363, BIBU-251, lefradafiban, BILA-2157BS, BILD-733, BIMG80, BIMU-1, DAU-6285, DS-AH-14, BIRR-4KD-IX-73-4, KO-286011, LT biosysthesis inhibitors, Boehringer, REN-1053, UD-CG-212, VZV inhibitors, BioMega/Boehringer Ingelheim, alinidine, apafant, bepafant, enlimomab, Ω interferon, BioMedicines, manganese SOD, Boehringer Ingelheim, mopidamol, muscarinic antagonists, Boehringer Ingelheim, abiraterone, cilobradine. Boehringer Ingelheim GmbH COMPANY COMMUNICATION 1997 July 22
8. 17α by abiraterone, a potential new drug for the treatment of prostate cancer. Jarman M, Barrie SE, Liera JM ANN ONCOL 1998 9 2 Abs 516
9. 17α by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3β-ol) and related steroidal inhibitors. Jarman M, Barrie SE, Liera JM J MED CHEM 1998 41 27 5375-5381
10. 316107 CB7598: A potent inhibitor of steroidal 17-α-hydroxylase/C17,20 lyase, a potential new drug for the treatment of prostate cancer. Barrie SE, Potter GA, Haynes BP, Jarman M J PHARM PHARMACOL 1995 47 12B 1076
11. 316110 Pharmacology of CB7598, a highly potent inhibitor of cytochrome P450c17. Haynes BP, Houghton J, King N, Barrie SE, Potter GA, Griggs LJ, Dowsett M, Jarman M PROC AM ASSOC CANCER RES 1994 35 San Francisco 420
12. 390644 Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17α-hydroxylase/C17-20-lyase (P450 17). Hartmann RW, Hector M, Wachall BG, Palusczak A, Palzer M, Huch V, Veith M J MED CHEM 2000 43 23 4437-4445
13. 422649 Novel nonsteroidal inhibitor of cytochrome P450(17α) (17α-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Ideyama Y, Kudoh M, Tanimoto K, Susaki Y, Nanya T, Nakahara T, Ishikawa H, Yoden T, Okada M, Fujikura T, Akaza H, Shikama H PROSTATE 1998 37 1 10-18
14. 533875 BTG licenses prostate cancer drug to Cougar. BTG International Ltd PRESS RELEASE 2004 April 20
15. 586126 Cougar Biotechnology presents CB7630 phase I clinical data at the 2005 Prostate Cancer Symposium. Cougar Biotechnology Inc PRESS RELEASE 2005 February 21
16. 586134 Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. BR J CANCER 2004 90 12 2317-2325
17. 614284 Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Handratta VD, Vasaitis TS, Njar VCO, Gediya LK, Kataria R, Chopra P, Newman DJ, Farquhar R, Guo Z, Brodie AMH J MED CHEM 2005 48 8 2972-2984
18. 614287 Effects of novel 17α-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW J STEROID BIOCHEM MOL BIOL 2003 84 5 555-562
19. 614288 In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17α-hydroxylase/C17,20-lyase. Duc I, Bonnet P, Duranti V, Cardinali S, Riviere A, De Giovanni A, Shields-Botella J, Barcelo G, Adje N, Carniato D, Lafay J, Pascal JC, Delansome R J STEROID BIOCHEM MOL BIOL 2003 84 5 537-542
20. 614294 17-(3-Pyridyl)substituted irreversible inhibitors of cytochrome P45017-α. Barrie SE, Potter GA, Jarman M BR J CANCER 1998 78 Suppl 1 33
21. 17α inhibitors. Barrie SE, Potter GA, Chan FC, Jarman M BR J CANCER 1997 75 Suppl 1 6
22. 614300 Highly potent inhibitors of human cytochrome P-450 (17α): Activity in vitro and in vivo. Barrie SE, Potter GA, Jarman M, Dowsett M BR J CANCER 1993 67 Suppl 20 75
23. 17α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostate cancer. Potter GA, Barrie SE, Jarman M, Rowland MG J MED CHEM 1995 38 13 2463-2471
24. 624806 Androgen deprivation therapy for prostate cancer. Sharifi N, Gulley JL, Dahut WL JAMA-J AM MED ASSOC 2005 294 2 238-244
25. 624810 A randomized phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen-independent prostate cancer and bone metastases. Figg WD, Liu Y, Arlen P, Gulley J, Lewis M, Dyer V, Chen C, Jones E, Forbes S, Kohler D, Trella A, Dahut WL J UROL 2005 173 3 790-796
26. 626695 The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M J UROL 2005 174 2 547-552
27. 631222 Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. Blagosklonny MV, Dixon SC, Figg WD J UROL 2000 163 3 1022-1026